[Current Data from the National Registry for Urothelial Cancer (UroNAT) by d-uo]

The German Association of Uro-Oncologists (d-uo) aims to document the real-world care in patients with urological tumor diseases, as well as to scientifically analyze and publish these data, thereby improving the quality of outpatient care.

UroNAT is a non-interventional, prospective, multicenter national registry for urothelial carcinomas initiated by d-uo in October 2021. Its objectives are continuous documentation, scientific evaluation, and quality assurance of treatment for patients with urothelial carcinoma at all stages in office-based outpatient care. This registry captures the cross-sectoral quality of care for urothelial carcinoma of the bladder and upper urinary tract in Germany. Currently, data from 1531 of 2024 enrolled patients are available for analysis in UroNAT.

In 69% of patients, presentation was driven by a symptom, predominantly gross hematuria or microscopic hematuria. Tumors were located in the urinary bladder in 94.5% of cases, and in the ureter or renal pelvis in 2% each. A solitary tumor was observed in 65% of patients, 2-7 tumors in 33%, and more than 8 tumors in 2%. Histologically, non-invasive tumor stages predominated (57% Ta, 20% T1), while 23% presented with T2-T4 disease. High-grade (G3) tumors accounted for 50% of cases, G2 for 26%, and G1 tumors for 24%; pure carcinoma in situ (CiS) was present in 3.9%. Approximately 90% of patients underwent TURB or re-TURB; cystectomy was performed in 5.1%, and procedures on the upper urinary tract or radiotherapy were carried out in fewer than 5%.

This nationwide registry allows all uro-oncological care providers from urology, oncology, and hospitals to participate via their outpatient clinics. With this national tumor registry, d-uo once again fulfills its commitment to comprehensive data collection in outpatient care research.